Anti‐CD20 Treatment Prolongs Syngeneic Islet Graft Survival and Delays the Onset of Recurrent Autoimmune Diabetes | Zendy

Hu Changyun | Zendy; Deng Songyan | Zendy; Wong F. Susan | Zendy; Wen Li | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Anti‐CD20 Treatment Prolongs Syngeneic Islet Graft Survival and Delays the Onset of Recurrent Autoimmune Diabetes

Author(s) -

Hu Changyun,

Deng Songyan,

Wong F. Susan,

Wen Li

Publication year - 2008

Publication title -

annals of the new york academy of sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.712

H-Index - 248

eISSN - 1749-6632

pISSN - 0077-8923

DOI - 10.1196/annals.1447.032

Subject(s) - islet , autoimmune diabetes , medicine , diabetes mellitus , immunology , autoimmune disease , autoimmunity , endocrinology , immune system , antibody

Type 1 diabetes is an autoimmune disease characterized by T cell–mediated destruction of pancreatic islet beta cells. Pancreatic islet transplantation with long‐term immunosuppressive drug treatment is an accepted therapeutic option for patients with type 1 diabetes suffering from disabling hypoglycemia on insulin treatment. Here we investigated the replacement of immunosuppressive drug treatment with immune tolerance establishment induced by temporary B cell–depletion therapy for islet transplantation. The result suggested that the combined therapy of B cell depletion and syngeneic islet transplantation may reverse the disease in hCD20/NOD mice.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research